SCHEMBL2818206

SCHEMBL2818206

CN(Cc1cccc(Br)c1)C1CC(C(=O)N2CCN(c3ccccc3C#N)CC2)N(Cc2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
MC4R P32245 1/20 0.39
DPP4 P27487 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
GRM5 P41594 1/20 0.38
PGR P06401 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
RORC P51449 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
MTOR P42345 1/20 0.36
RPTOR Q8N122 1/20 0.36
MLST8 Q9BVC4 1/20 0.36
SHH Q15465 1/20 0.36
SMO Q99835 1/20 0.36
JAK2 O60674 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818773 0.92 MC4R (0.40) MC4RDPP4GRM5PGRCYP2D6
SCHEMBL13841885 0.92 MC4R (0.43) MC4RDPP4GRM5PGRCYP2D6
SCHEMBL13841910 0.92 MC4R (0.43) MC4RDPP4GRM5PGRCYP2D6
SCHEMBL3975756 0.91 HRH3 (0.42) MC4RDPP4HTR1AHTR1DHTR1B
SCHEMBL2817641 0.89 CHRM4 (0.44) POLBMC4RDPP4HTR1AHTR1D
SCHEMBL2821462 0.89 MC4R (0.41) MC4RDPP4HTR1AHTR1DHTR1B
SCHEMBL2819575 0.89 MC4R (0.41) MC4RDPP4HTR1AHTR1DHTR1B
SCHEMBL2820841 0.88 MC4R (0.40) MC4RDPP4GRM5PGRCYP2D6
SCHEMBL2820315 0.87 DPP4 (0.41) MC4RDPP4GRM5PGRCYP2D6
SCHEMBL2819553 0.87 MC4R (0.43) MC4RDPP4GRM5PGRCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 POLB 2983/4885MC4R 623/4885DPP4 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.